Ecsponent set to grow in 2016

Ecsponent has an established reputation for a forward-thinking approach to organic and acquisitive growth strategy and a strong future-based investment philosophy. Our CEO, Euné Engelbrecht, is confident that by seeking out value-enhancing acquisitions we will continue to reflect solid growth for our investors.   The latest notice to shareholders forecasts that for the year ended…

Details

Biotech remains an increasingly bullish investment sector

Salveo Swiss Biotechnology and Cryo-Save form part of Ecsponent Limited’s investment strategy to acquire interests and develop technology businesses with high intellectual property and high barriers to entry.   Ecsponent’s investment in the biotech sector provides South African clients with international, industry leading stem cell storage within the biotechnology arena and is an example of…

Details